You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Heart Rate Variability Analysis Using Polynomial Network

    SBC: ABTECH CORPORATION            Topic: N/A

    High-risk newborn infants in an intensive care unit often suffer significant morbidity and mortalitybecause of infectious illnesses which elude early diagnosis and are present in advanced stages withcirculatory shock. Earlier diagnosis and therapy might present in advanced stages with circulatoryshock. Earlier diagnosis and therapy might prevent or reduce late complications and deaths. A strategyf ...

    SBIR Phase I 1994 Department of Health and Human Services
  2. HEART RATE VARIABILITY ANALYSIS USING POLYNOMIAL NETWORK

    SBC: ABTECH CORPORATION            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  3. LONG RANGE POPULATION PROJECTION BY DISABILITY STATUS

    SBC: Actuarial Research Corporation            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  4. PSO ACTUARIAL RATE MODEL FOR MEDICARE RISK CONTRACTS

    SBC: Actuarial Research Corporation            Topic: N/A

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  5. Long Acting Agonists of Adenosine A2a Receptors

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Adenosine is an endogenous nucleoside that exerts its physiological effects through four G-protein coupled receptors A1, A2A, A2B, and A3. Adenosine Therapeutics, LLC is interested in the anti-inflammatory actions mediated by the A2A receptor subtype. A lead compound, ATL-146e, is being developed for coronary artery imaging and has also been shown to be effi ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Improved Outcome Prediction In Galactosemic Newborns

    SBC: ADVANCED BREATH DIAGNOSTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Galactosemia is a potentially lethal, but preventable, disease of newborns. In Phase I of this grant, we demonstrated that a 13C-galactose breath test could be used to assess the degree of impairment of whole body galactose oxidation in more than 90 galactosemic children with a broad spectrum of mutations in the human GALT gene that codes for galactose-l-phosph ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  7. TRAINING SECONDARY PREVENTION OF FETAL ALCOHOL SYNDROME

    SBC: Alcohol Self-control Program            Topic: N/A

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  8. Multimedia Self-Help for Teenagers to Reduce Child Abuse

    SBC: American Research Corporation of Virginia            Topic: N/A

    The National Institute for Mental Health has reported the need for development and evaluationof behavioral self-help core materials for the promotion of health and healthy lifestyles. Teenage mothersare a particularly important segment of the population in need of such a self-help course devoted toparenting skills and stress control. Unfortunately, teenage mothers generally lack knowledge of child ...

    SBIR Phase I 1994 Department of Health and Human Services
  9. Aptamer Array Finds Metabolic Change from Hepatotoxicity

    SBC: American Research Corporation of Virginia            Topic: N/A

    DESCRIPTION (provided by applicant): In order to reduce the costs of drug development and improve methods of detecting environmental effects of xeniobiotics, there is a need for in vitro methods of xeniobiotics identifying toxicity of materials to specific organs that do not require a whole-animal model. In particular, methods capable of identifying hepatotoxicity either require extensive animal ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  10. N/A

    SBC: American Research Corporation of Virginia            Topic: N/A

    N/A

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government